Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

1.

Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer.

Nakai Y, Tatsumi Y, Miyake M, Anai S, Masaomi K, Onishi S, Chihara Y, Tanaka N, Hirao Y, Fujimoto K.

Photodiagnosis Photodyn Ther. 2015 Jul 27. pii: S1572-1000(15)30012-0. doi: 10.1016/j.pdpdt.2015.07.174. [Epub ahead of print] No abstract available.

PMID:
26226642
2.

Review by urological pathologists improves the accuracy of Gleason grading by general pathologists.

Nakai Y, Tanaka N, Shimada K, Konishi N, Miyake M, Anai S, Fujimoto K.

BMC Urol. 2015 Jul 23;15:70. doi: 10.1186/s12894-015-0066-x.

3.

Clinical significance and therapeutic potential of prostate cancer antigen-1/ALKBH3 in human renal cell carcinoma.

Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, Harada H, Tsujikawa K, Konishi N, Shinohara N, Nakajima Y.

Oncol Rep. 2015 Aug;34(2):648-54. doi: 10.3892/or.2015.4017. Epub 2015 May 29.

PMID:
26035443
4.

A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide.

Nakai Y, Tanaka N, Anai S, Miyake M, Tatsumi Y, Fujimoto K.

Horm Cancer. 2015 Aug;6(4):161-7. doi: 10.1007/s12672-015-0226-1. Epub 2015 May 30.

PMID:
26024831
5.

Changes in lower urinary tract symptoms and quality of life after salvage radiotherapy for biochemical recurrence of prostate cancer.

Miyake M, Tanaka N, Asakawa I, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Yoneda T, Hasegawa M, Konishi N, Fujimoto K.

Radiother Oncol. 2015 Jun;115(3):321-6. doi: 10.1016/j.radonc.2015.04.026. Epub 2015 May 16.

PMID:
25991382
6.

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.

Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, Okajima E, Hirayama A, Hirao Y, Fujimoto K.

BMC Cancer. 2015 May 20;15:420. doi: 10.1186/s12885-015-1429-0.

7.

Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute.

Miyake M, Gotoh D, Shimada K, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Konishi N, Fujimoto K.

Int J Urol. 2015 Jun;22(6):541-7. doi: 10.1111/iju.12749. Epub 2015 Apr 8.

PMID:
25857336
8.

Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A randomized, double-blind, multicentre phase II/III study.

Inoue K, Anai S, Fujimoto K, Hirao Y, Furuse H, Kai F, Ozono S, Hara T, Matsuyama H, Oyama M, Ueno M, Fukuhara H, Narukawa M, Shuin T.

Photodiagnosis Photodyn Ther. 2015 Jun;12(2):193-200. doi: 10.1016/j.pdpdt.2015.03.008. Epub 2015 Apr 2.

PMID:
25843912
9.

Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer.

Nakai Y, Anai S, Onishi S, Masaomi K, Tatsumi Y, Miyake M, Chihara Y, Tanaka N, Hirao Y, Fujimoto K.

Photodiagnosis Photodyn Ther. 2015 Jun;12(2):282-8. doi: 10.1016/j.pdpdt.2014.12.010. Epub 2015 Jan 13.

PMID:
25595357
10.

Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil.

Tanaka N, Torimoto K, Asakawa I, Miyake M, Anai S, Hirayama A, Hasegawa M, Konishi N, Fujimoto K.

Radiat Oncol. 2014 Dec 29;9:302. doi: 10.1186/s13014-014-0302-7.

11.

Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.

Nozawa M, Ohzeki T, Tamada S, Hongo F, Anai S, Fujimoto K, Miki T, Nakatani T, Fukasawa S, Uemura H.

Int J Clin Oncol. 2014 Oct 25. [Epub ahead of print]

PMID:
25342378
12.

Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study.

Miyake M, Tanaka N, Asakawa I, Morizawa Y, Anai S, Torimoto K, Aoki K, Yoneda T, Hasegawa M, Konishi N, Fujimoto K.

Radiat Oncol. 2014 Oct 20;9:208. doi: 10.1186/1748-717X-9-208.

13.

A patient with medulloblastoma in its early developmental stage.

Shinojima N, Nakamura H, Tasaki M, Kameno K, Anai S, Iyama K, Ando Y, Seto H, Kuratsu J.

J Neurosurg Pediatr. 2014 Dec;14(6):615-20. doi: 10.3171/2014.8.PEDS13590. Epub 2014 Oct 10.

PMID:
25303160
14.

Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid.

Nakai Y, Anai S, Kuwada M, Miyake M, Chihara Y, Tanaka N, Hirayama A, Yoshida K, Hirao Y, Fujimoto K.

BMC Urol. 2014 Aug 3;14:59. doi: 10.1186/1471-2490-14-59.

15.

[The control of respiratory organ motion in the field of radiology: the viewpoint of a radiation oncologist].

Nakamura K, Yoshitake T, Terashima K, Sasaki T, Ohga S, Asai K, Matsumoto K, Hirata H, Shinoto M, Yoshidome S, Anai S, Shioyama Y, Honda H.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2014 May;70(5):477-82. Japanese. No abstract available.

16.

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer.

Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, Okajima E, Hirayama A, Hirao Y, Fujimoto K.

BMC Urol. 2014 Apr 29;14:33. doi: 10.1186/1471-2490-14-33.

17.

Antitumor effect of fibrin glue containing temozolomide against malignant glioma.

Anai S, Hide T, Takezaki T, Kuroda J, Shinojima N, Makino K, Nakamura H, Yano S, Kuratsu J.

Cancer Sci. 2014 May;105(5):583-91. doi: 10.1111/cas.12397. Epub 2014 Apr 19.

PMID:
24673719
18.

Follow-up study of unilateral renal function after nephrectomy assessed by glomerular filtration rate per functional renal volume.

Hosokawa Y, Tanaka N, Mibu H, Anai S, Torimoto K, Yoneda T, Hirayama A, Yoshida K, Hayashi Y, Hirao Y, Fujimoto K.

World J Surg Oncol. 2014 Mar 19;12:59. doi: 10.1186/1477-7819-12-59.

19.

Diagnostic approach for cancer cells in urine sediments by 5-aminolevulinic acid-based photodynamic detection in bladder cancer.

Miyake M, Nakai Y, Anai S, Tatsumi Y, Kuwada M, Onishi S, Chihara Y, Tanaka N, Hirao Y, Fujimoto K.

Cancer Sci. 2014 May;105(5):616-22. doi: 10.1111/cas.12393. Epub 2014 Apr 6.

PMID:
24602011
20.

Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.

Shimada K, Anai S, Fujii T, Tanaka N, Fujimoto K, Konishi N.

J Pathol. 2013 Dec;231(4):495-504. doi: 10.1002/path.4271.

PMID:
24549646
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk